There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.
There is greater overall survival (OS) benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of a randomized trial.
During the 2018 Genitourinary Cancers Symposium, Joaquim Bellmunt, MD, PhD, of the Dana Farber Institute, presented results from a median follow-up of 27.7 months of the KEYNOTE-045 trial, which compared pembrolizumab versus the investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer as second-line treatment.
Between November 2014 and November 2015, 542 patients were enrolled in the trial. Participants were randomized 1:1 to the immunotherapy arm to receive 200 mg of pembrolizumab intravenously every 3 weeks, or to the chemotherapy arm to receive 1 of the following: 175 mg/m2 of paclitaxel every 3 weeks, 75 mg/m2 of docetaxel every 3 weeks, or 320 mg/m2 of vinflunin every 3 weeks.
The dual primary endpoints were OS and progression-free survival (PFS). Key secondary endpoints were objective response rate (ORR), duration of response, and safety. Tumors were assessed at week 9 and every 6 weeks following for a 1-year duration, and then were assessed every 12 weeks thereafter. PD-L1 status was also obtained; it was considered positive when more than 10% of tumor and immune cells showed PD-L1 expression.
In the pembrolizumab arm, 26 patients were able to complete 2 years of therapy, while none in the chemotherapy arm were able to do so. The researchers also saw 10 complete responses in the pembrolizumab arm, compared with 1 in the chemotherapy arm.
Following 27.7 months of follow-up, the median OS was 10.3 months for participants treated with pembrolizumab versus 7.3 months for participants treated with chemotherapy. The 12-month OS was 44.4% for the pembrolizumab arm compared to 29.8% in the chemotherapy arm; 24-month OS was almost doubled in the pembrolizumab arm, at 27% (compared to 14.3% in the chemotherapy arm).
At 24 months, 60.6% of participants in the chemotherapy arm received an immunotherapeutic agent, including those who received pembrolizumab as part of the crossover, according to Bellmunt.
Although there were no significant differences in PFS at 14 or 27.7 months of follow-up, the authors did see that the proportion of participants that remained progression free was greater in the pembrolizumab arm at 12 months (18.4% versus 9.5%) and at 24 months (12.5% versus 2.5%).
ORR was almost double in the pembrolizumab arm (21.1% versus 11%), and the pembrolizumab arm saw fewer adverse events compared with the chemotherapy arm.
“Pembrolizumab is the first immunotherapy to demonstrate superior survival over chemotherapy in patients with advanced urothelial carcinoma after failure of platinum-based therapy,” concluded Bellmunt. “This is level 1 evidence that supports the use of pembrolizumab as a standard of care for this patient population.”
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More